Ann Kolanowski1, Jacqueline Mogle2, Donna M Fick2, Noll Campbell3, Nikki Hill2, Paula Mulhall2, Liza Behrens2, Elise Colancecco2, Malaz Boustani4, Linda Clare5. 1. College of Nursing, Penn State, University Park, PA, USA. Electronic address: amk20@psu.edu. 2. College of Nursing, Penn State, University Park, PA, USA. 3. Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, IN, USA. 4. Regenstrief Institute, Indianapolis, IN, USA; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. 5. REACH: The Centre for Research in Ageing and Cognitive Health, College of Life and Environmental Sciences, Department of Psychology, Washington Singer Laboratories, Exeter, UK.
Abstract
OBJECTIVES: We examined the association between anticholinergic medication exposure and subsequent cognitive and physical function in patients with delirium superimposed on dementia during rehabilitation. We also examined length of stay and discharge disposition by anticholinergic medication exposure. DESIGN: In this secondary analysis we used control group data from an ongoing randomized clinical trial. SETTING/PARTICIPANTS: Participants with delirium and dementia were enrolled at admission to post-acute care. These 99 participants had a mean age of 86.11 (±6.83) years; 67.6% were women; 98% were Caucasian; and 33% were positive for at least one APOE e4 allele. MEASURES: We obtained daily measures of cognitive and physical function using: Digit Span; memory, orientation and attention items from the Montreal Cognitive Assessment; CLOX; the Confusion Assessment Method; and the Barthel Index. Anticholinergic medication exposure was measured weekly using the Anticholinergic Cognitive Burden Scale. RESULTS: Using multilevel models for time we found that greater use of clinically relevant anticholinergic medications in the previous week reduced cognitive and physical function, as measured by Digit Span Backwards and the Barthel index, in the current week. There was no effect of anticholinergic medication use on delirium severity, and APOE status did not moderate any outcomes. Greater use of clinically relevant anticholinergic medications was related to longer length of stay but not discharge disposition. CONCLUSIONS: For vulnerable older adults, anticholinergic exposure represents a potentially modifiable risk factor for poor attention, working memory, physical function, and greater length of stay during rehabilitation.
RCT Entities:
OBJECTIVES: We examined the association between anticholinergic medication exposure and subsequent cognitive and physical function in patients with delirium superimposed on dementia during rehabilitation. We also examined length of stay and discharge disposition by anticholinergic medication exposure. DESIGN: In this secondary analysis we used control group data from an ongoing randomized clinical trial. SETTING/PARTICIPANTS: Participants with delirium and dementia were enrolled at admission to post-acute care. These 99 participants had a mean age of 86.11 (±6.83) years; 67.6% were women; 98% were Caucasian; and 33% were positive for at least one APOE e4 allele. MEASURES: We obtained daily measures of cognitive and physical function using: Digit Span; memory, orientation and attention items from the Montreal Cognitive Assessment; CLOX; the Confusion Assessment Method; and the Barthel Index. Anticholinergic medication exposure was measured weekly using the Anticholinergic Cognitive Burden Scale. RESULTS: Using multilevel models for time we found that greater use of clinically relevant anticholinergic medications in the previous week reduced cognitive and physical function, as measured by Digit Span Backwards and the Barthel index, in the current week. There was no effect of anticholinergic medication use on delirium severity, and APOE status did not moderate any outcomes. Greater use of clinically relevant anticholinergic medications was related to longer length of stay but not discharge disposition. CONCLUSIONS: For vulnerable older adults, anticholinergic exposure represents a potentially modifiable risk factor for poor attention, working memory, physical function, and greater length of stay during rehabilitation.
Authors: S K Inouye; S T Bogardus; P A Charpentier; L Leo-Summers; D Acampora; T R Holford; L M Cooney Journal: N Engl J Med Date: 1999-03-04 Impact factor: 91.245
Authors: Alessandro Morandi; Giuseppe Bellelli; Eduard E Vasilevskis; Renato Turco; Fabio Guerini; Tiziana Torpilliesi; Salvatore Speciale; Valeria Emiliani; Simona Gentile; John Schnelle; Marco Trabucchi Journal: J Am Med Dir Assoc Date: 2013-05-07 Impact factor: 4.669
Authors: Ann M Kolanowski; Donna M Fick; Mark S Litaker; Linda Clare; Doug Leslie; Malaz Boustani Journal: Trials Date: 2011-05-11 Impact factor: 2.279
Authors: Lauren Massimo; Elizabeth Munoz; Nikki Hill; Jacqueline Mogle; Paula Mulhall; Corey T McMillan; Linda Clare; David Vandenbergh; Donna Fick; Ann Kolanowski Journal: Int J Geriatr Psychiatry Date: 2016-04-27 Impact factor: 3.485
Authors: Lana Sargent; Mike Nalls; Angela Starkweather; Sarah Hobgood; Holly Thompson; Elaine J Amella; Andrew Singleton Journal: Ageing Res Rev Date: 2018-08-10 Impact factor: 10.895
Authors: Angelique Egberts; Saskia T van der Craats; Melissa D van Wijk; Shams Alkilabe; Patricia M L A van den Bemt; Francesco U S Mattace-Raso Journal: Pharmacol Res Perspect Date: 2017-05-11
Authors: James A G Crispo; Allison W Willis; Dylan P Thibault; Yannick Fortin; Harlen D Hays; Douglas S McNair; Lise M Bjerre; Dafna E Kohen; Santiago Perez-Lloret; Donald R Mattison; Daniel Krewski Journal: PLoS One Date: 2016-03-03 Impact factor: 3.240